Taraf and internationally renowned fashion house KARL LAGERFELD have signed a partnership agreement to collaborate on luxury branded villas in Dubai. The project, set to launch in the coming months, will be KARL LAGERFELD’S third branded residential property in the world and the first in the Middle East. In 2021, the fashion house launched luxury
25/07/2023
Taraf Launches Terrazzo Residences, a Curated Residential Property in Jumeirah Village Circle
Taraf has launched Terrazzo Residences in Dubai’s popular community of Jumeirah Village Circle (JVC). The company’s second project reflects its aim to create unique experiences and elevate community living. The exquisite Terrazzo Residences incorporates high-end finishing and connects residences with the outdoors through spacious apartments of glass façades, an infinity pool and expansive terraces –
25/04/2023
Elite Global Fresh Trading expands export of popular UAE-grown blueberries to new markets in Asia-Pacific
Elite Global Fresh Trading (EGFT) has expanded its international footprint by exporting highly in-demand blueberries to the new destinations of Japan, Cambodia, Thailand and India, adding to its existing export markets of Singapore, Malaysia and Hong Kong. EAG is the first and biggest producer in the UAE to grow blueberries, and the first Emirati company
21/02/2023
Taraf sets a new record in Real Estate as exclusive property LUCE sells out within hours of launch
Taraf, a prime residential property developer, achieved a remarkable feat as its first project, Luce, sold out all its exclusive units within hours of its launch. This prominent launch reflects the high standards and quality of the project, the strong partnerships with stakeholders in the market as well as the interest from buyers for iconic
16/02/2023
Taraf launches Luce, a bright new landmark on Palm Jumeirah
Luce residences offer beachfront luxury, comfort and privacy for a highly curated living experience Taraf, has revealed its first property – Luce, a new landmark on Dubai’s Palm Jumeirah, offering contemporary luxury and an enhanced living experience in spacious light-filled homes with sweeping panoramic views. Luce guarantees unrivalled waterfront views over Dubai’s coveted blue waters
02/02/2023
Bioventure and Al Razi Partners up With an Exclusive License Agreement for Oncology Product in KSA Market
Bioventure FZ LLC (“Bioventure”) and Al Razi Pharma Industries (“Al Razi”) sign an exclusive agreement for the commercialisation of an oncology product in the Kingdom of Saudi Arabia. Bioventure, a subsidiary of Yas Holding’s healthcare division GlobalOne Healthcare Holding (GHH), and Al Razi Pharma Industries, a Saudi national pharmaceutical company which is a subsidiary of
01/02/2023
Bioventure and AJA Pharma Sign MoU Leveraging Existing Strategic Partnership
Bioventure FZ-LLC and AJA Pharmaceuticals, a subsidiary of Saudi Chemical Company Holding (SCCH) signed a Memorandum of Understanding (MoU) to strengthen the existing strategic partnership between the two institutions. The collaboration will focus on diabetes, oncology and biosimilars, therapeutic categories that are forecasted to be among the largest and fastest-growing within the global pharma sector
01/02/2023
Bioventure and Amman Pharma Sign an Exclusive Licensing Agreement for the Commercialisation of Aflibercept in the Levant region
Bioventure, a subsidiary of GlobalOne Healthcare Holding within Yas Holding’s healthcare division, has partnered with Amman Pharmaceutical Industries, a leading pharmaceutical manufacturer with operations across the MENA region and other markets, to bring Aflibercept, a biosimilar of Bayer’s Eylea, to patients in the Levant region. The partnership grants Amman Pharma exclusive rights to register, hold
27/01/2023
Alvotech and Bioventure announce approval of AVT02 (adalimumab) as Simlandi in KSA
Alvotech (NASDAQ: ALVO) and Bioventure, announced that the Saudi Food & Drug Authority (“SFDA”) has approved the manufacturing and distribution of AVT02, a biosimilar for Humira® (adalimumab), which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases. The biosimilar will be marketed as Simlandi™ in Saudi Arabia. A biosimilar is
26/01/2023
Bioventure extends its strategic collaboration with Adalvo a leading B2B pharmaceutical company in Europe
Bioventure has extended its strategic partnership with Adalvo, the global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, by signing a licensing deal for four molecules, within the MENA region. The products are indicated in a variety of treatments including oncology, urinary tract infection, and anti-infective. With this collaboration, Adalvo is